

September 18, 2026

To

BSE Limited,

Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

National Stock Exchange of India Limited,

Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Scrip Code: 540679

Trading Symbol: HALEOSLABS

SUB: UPDATE ON "US-FDA" INSPECTION OF MATERIAL SUBSIDIARY.

Ref: Reg. 30 (9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In continuation of our earlier communication dated January 24, 2025, we are pleased to inform that the United States Food and Drug Administration (USFDA) has successfully conducted an inspection of Mahi Drugs Private Limited, Material Subsidiary of the Company, at its API manufacturing facility located at Plot No. 82, Jawaharlal Nehru Pharma City, Parawada, Anakapalli – 531019, Andhra Pradesh, from September 15, 2026 to September 18, 2026.

We are pleased to inform that the inspection has been successfully concluded with zero Form 483 observations, thereby achieving the same outcome as the previous USFDA inspection conducted at the said facility in January 2025.


This outcome reflects the Company's continued commitment to maintaining the highest standards of regulatory compliance, quality and operational excellence.

The above information is also available on the website of the Company www.haleoslabs.com

Please take the same on record and suitably disseminate to all concerned.

For Haleos Labs Limited

(Formerly known as "SMS Lifesciences India Limited")


Trupti Ranjan Mohanty

Company Secretary



Haleos Labs Limited

(Formerly SMS Lifesciences India Limited)

Registered & Corporate Office: Plot No. 19-III, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad – 500 096, Telangana, India.

Tel: +91-40-6628 8888 | CIN - L74930TG2006PLC050223 | info@haleoslabs.com | www.haleoslabs.com